Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

3147results about "Multivalent vaccine" patented technology

Pan-human coronavirus vaccines

The disclosure relates to pan human coronavirus ribonucleic acid (RNA) vaccines as well as methods of using the vaccines and compositions comprising the vaccines.
Owner:MODERNATX INC

BETACORONAVIRUS mRNA VACCINES

The disclosure relates to ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines. Specific embodiments relate to RNA betacoronavirus vaccines formulated in a lipid nanoparticle.
Owner:MODERNATX INC

BETACORONA VIRUS mRNA VACCINES

The disclosure relates to ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines. Specific embodiments relate to RNA betacoronavirus vaccines formulated in a lipid nanoparticle.
Owner:MODERNATX INC

Compositions comprising a norovirus nucleic acid and methods of use thereof

The present invention is directed to an artificial nucleic acid and to polypeptides suitable for use in treatment or prophylaxis of an infection with Norovirus or a disorder related to such an infection. In particular, the present invention concerns a Norovirus vaccine. The present invention is directed to an artificial nucleic acid, polypeptides, compositions and vaccines comprising the artificial nucleic acid or the polypeptides. The invention further concerns a method of treating or preventing a disorder or a disease, first and second medical uses of the artificial nucleic acid, polypeptides, compositions and vaccines. Further, the invention is directed to a kit, particularly to a kit of parts, comprising the artificial nucleic acid, polypeptides, compositions and vaccines.
Owner:CUREVAC SE

Combination containing an mRNA vaccine or an mRNA encoded therapeutic protein and an immune modulating mRNA for improved or reduced immunogenicity to increase efficacy

The present invention pertains to a combination comprising two or more mRNA molecules, or a single mRNA molecule encoding a first molecule, which is a therapeutic or immunogenic protein or peptide, and a second molecule, which is a protein or a peptide having the ability to modulate an immune response against the first molecule and / or the translation product of the first molecule, wherein the combination comprises at least one first mRNA molecule encoding a first molecule, which is a therapeutic or immunogenic protein or peptide, and at least one second mRNA molecule encoding a second molecule, which is a protein or a peptide having the ability to modulate an immune response against the first molecule and / or the translation product of the first molecule. The invention also relates to a host cell comprising a combination or the single mRNA molecule according to the present invention, a pharmaceutical composition comprising the combination, the single mRNA molecule, or the host cell of the present invention, and a vaccine comprising the combination, the single mRNA molecule, the host cell, or the pharmaceutical composition according to the present invention. Further provided is a kit comprising the combination, the single mRNA molecule, the host cell, the pharmaceutical composition, or the vaccine according to the present invention. The invention also pertains to the combination, the single mRNA molecule, the host cell, the pharmaceutical composition, the vaccine, or the kit according to the present invention, for use in medicine. Finally, the invention also relates to the combination, the single mRNA molecule, the host cell, the pharmaceutical composition, the vaccine, or the kit according to the present invention, for use in a method of prevention, and / or treatment of an infectious, a genetic, or a proliferative disease.
Owner:IMGEN-T-SRL

Graisseria parasuis three-component subunit vaccine and preparation method thereof

The invention discloses a Graisseria parasuis three-component subunit vaccine and a preparation method thereof, and belongs to the technical field of biology. The vaccine comprises three kinds of antigen proteins of the Gleisseria parasuis in an immunizing dose and a pharmaceutically acceptable adjuvant, and the amino acid sequences of the three kinds of antigen proteins are respectively shown as SEQ ID NO.1, SEQ ID NO.2 and SEQ ID NO.3. The invention further discloses a preparation method of the vaccine. The three-component subunit vaccine provided by the invention has cross protection force on infection of type-4 and type-5 Graisseria parasuis, has an excellent immune protection effect, and is expected to play a better role in prevention and control of infectious diseases caused by the Graisseria parasuis.
Owner:WUHAN KEQIAN BIOLOGY CO LTD

Recombinant Marek's disease virus co-expressing Newcastle disease virus F gene and infectious bursal disease virus supervirulent strain VP2 gene and application of recombinant Marek's disease virus

The invention provides a recombinant Marek's disease virus co-expressing a Newcastle disease virus F gene and an infectious bursal disease virus supervirulent strain VP2 gene and application thereof, and belongs to the field of genetic engineering vaccines. According to the invention, by using a recombinant cloning technology, an expression framework containing a Newcastle disease virus gene VII type strain F gene and an infectious bursal disease virus super virulent strain VP2 gene is inserted into a spacer region between Marek's disease virus genome UL45 and UL46 genes; according to the method, a recombinant cosmid is constructed and obtained, wherein a Newcastle disease virus F gene and an infectious bursal disease virus super virulent strain VP2 gene expression framework are inserted between Marek's disease virus genome UL45 and UL46 genes, and a recombinant virus C20101 strain co-expressing the Newcastle disease virus F gene and the infectious bursal disease virus super virulent strain VP2 gene is rescued and obtained by the recombinant cosmid. The vaccine prepared from the recombinant Marek's disease virus strain provided by the invention can prevent Newcastle disease, chicken infectious bursal disease and Marek's disease at the same time, and has a good market application prospect.
Owner:INST OF URBAN AGRI CHINESE ACADEMY OF AGRI SCI +1

Multivalent pneumococcal polysaccharide-protein conjugate vaccine as well as preparation method and application thereof

The invention relates to the technical field of biology, in particular to a multivalent pneumococcal polysaccharide-protein conjugate vaccine for preventing pneumococcal infection and respiratory syncytial virus infection as well as a preparation method and application of the multivalent pneumococcal polysaccharide-protein conjugate vaccine. According to the multivalent pneumococcal polysaccharide-protein conjugate vaccine disclosed by the invention, carrier protein is RSV recombinant protein with immunogenicity; the pneumococcal polysaccharide is connected with the RSV recombinant protein through a covalent bond; the RSV recombinant protein is selected from Pre-F protein, and the amino acid sequence of the RSV recombinant protein is shown as SEQ ID NO: 2 or SEQ ID NO: 3. The conjugate vaccine provided by the invention is an innovative vaccine, two common diseases, namely pneumonia and respiratory syncytial virus infection, can be simultaneously prevented by using one vaccine product, and the number of vaccination times of the vaccine is greatly reduced. According to the invention, the carrier protein in the conjugate vaccine is subjected to mutation modification, so that the carrier protein can maintain structural stability and antigen cluster function in different environments.
Owner:UNIVERSALVAX BIOTECHNOLOGIES (TAIZHOU) CO LTD

Vaccine composition and application thereof

The present disclosure provides a vaccine composition wherein the antigen components comprise a factor H binding protein (fHbp), a recombinant outer membrane vesicle (OMV) carrying porin A (PorA protein), and optionally a heparin binding protein (NHBA protein). The antigen components in the vaccine composition disclosed by the invention have a good synergistic effect, so that the vaccine composition has extremely high vaccine forming potential, is used for preventing epidemic of group B meningococcus, and plays a role in protecting infection of group B meningococcus.
Owner:SINOVAC RES & DEV CO LTD

LIPID NANOPARTICLE mRNA VACCINES

PendingUS20250288522A1SsRNA viruses negative-sensePowder deliveryAntigenRabies vaccination
The invention relates to mRNA comprising lipid nanoparticles and their medical uses. The lipid nanoparticles of the present invention comprise a cationic lipid according to formula (I), (II) or (III) and / or a PEG lipid according to formula (IV), as well as an mRNA compound comprising an mRNA sequence encoding an antigenic peptide or protein. The invention further relates to the use of said lipid nanoparticles as vaccines or medicaments, in particular with respect to influenza or rabies vaccination.
Owner:CUREVAC SE +1

Hybrid flu-coronavirus vaccine

A hybrid vaccine composition that prevents infection or reinfection by both influenza and coronaviruses, comprising at least a portion of a Coronavirus spike(S) protein and at least a portion of at least one influenza hemagglutinin (HA) protein. The portion of the coronavirus spike(S) protein is highly conserved among human and animal coronaviruses. The vaccine composition may comprise a Coronavirus protein comprising either: a structural protein, e.g., a Spike protein, a Nucleocapsid protein, or a combination thereof, or a non-structural protein, e.g., NSP2, NSP3, NSP14, or combination thereof; and at least a portion of at least one influenza hemagglutinin (HA) protein.
Owner:RGT UNIV OF CALIFORNIA

Respiratory syncytial virus (RSV) polypeptide with immunogenicity

The invention provides a respiratory syncytial virus (RSV) polypeptide with immunogenicity, and relates to the technical field of biological medicines. The stable pre-fusion F protein is successfully constructed and expressed by utilizing an extracellular domain of RSV F protein recombination, the stability of the pre-fusion conformation F protein is enhanced through mutation design of different disulfide bonds, and the obtained antigen and the vaccine prepared from the antigen are high in expression quantity, good in stability and high in immunogenicity.
Owner:JIANGSU RECBIO TECH CO LTD +1

Universal vaccine platform

The disclosure relates to vaccination compositions, for example, against human papillomavirus, Zika virus, and flu virus. The disclosure also relates to vectors for producing the virus-like particles and immune complex platforms of the vaccination compositions.
Owner:THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIV OF ARIZONA

Fusion protein for preventing and treating various pathogenic streptococcus infections and application thereof

PendingCN120842431ABacterial antigen ingredientsAntibacterial agentsStreptococcus infectionSerotype
The invention relates to a fusion protein, an immunogenic composition and a recombinant degenerate vaccine for preventing and treating infection of various pathogenic streptococci, as well as a molecular architecture design, application and the like. According to the invention, three immune antigens, namely an elongation factor Tu (Tuf), a molecular chaperone DnaK and an elongation factor G (fusA), are screened, and it is proved that fusion protein molecules of the three antigens can significantly inhibit tissue lesions caused by infection of different serotypes and different types of streptococci, have good immunogenicity, play roles in immune protection and effective prevention and treatment, and have good application prospects. The bacillus subtilis has the characteristics of broad-spectrum and high-efficiency prevention of streptococcus bacterial infection, and has a wide application prospect.
Owner:NANJING CHENGSHI BIOMEDICAL TECH CO LTD

Preparation and application of combined subunit vaccine for hemorrhagic disease and septicemia of grass carp

The invention discloses preparation and application of a combined subunit vaccine for hemorrhagic disease and septicemia of grass carp. The invention provides a fusion gene obtained by connecting VP6 protein of GCRV and ompAII protein of aeromonas veronii, the fusion gene expresses fusion protein and is combined with an adjuvant to construct a biunit vaccine for intraperitoneal injection immunization of an experimental animal, spleen and kidney tissues are collected, and the expression level of immune related genes in each tissue is measured; results show that the prepared bivalent subunit vaccine can stimulate different immune tissues of a fish body to generate immune response reaction through injection immunization; gCRV virulent virus and aeromonas veronii are injected into the abdominal cavity for a fish body challenge experiment on the 28th day after immunization, and the relative survival rates of aeromonas veronii and grass carp reovirus infection are 85% and 55% respectively 15 days after challenge, so that the bivalent subunit vaccine disclosed by the invention has a relatively good protection effect on important diseases of cultured grass carp.
Owner:PEARL RIVER FISHERY RES INST CHINESE ACAD OF FISHERY SCI

Swine influenza a virus vaccine

The present invention provides vectors and / or nucleic acid constructs that encode one or more influenza A virus neuraminidase (NA) antigens. The present invention also provides vaccine against influenza A virus comprising such vectors and / or nucleic acid constructs. The present invention further provides methods of making and using the vaccines alone, or in combination with other protective agents.
Owner:INTERVET INC

Concatemeric peptide epitope RNAs

The invention relates to concatemeric peptide epitope RNAs, as well as methods and compositions thereof. mRNA vaccines are also provided according to the invention, including cancer vaccines.
Owner:MODERNATX INC

Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy

The present invention relates to methods for predicting whether peptides or polypeptides comprising disease specific amino acid modifications, in particular tumor-associated neo-antigens, comprise epitopes, in particular tumor-associated neo-epitopes, which are useful for immunotherapy such as for vaccination. The methods of the invention may be used, in particular, for the provision of vaccines which are specific for a patient's tumor and, thus, in the context of personalized cancer vaccines.
Owner:BIONTECH SE

H1N1 broad-spectrum mRNA (messenger ribonucleic acid) vaccine taking HA (hemagglutinin) and NA (nitrosamine) protein tandem as target and preparation method thereof

The invention provides an H1N1 broad-spectrum mRNA (messenger ribonucleic acid) vaccine taking HA (hemagglutinin) and NA (neuraminidase) protein tandem as a target and a preparation method of the H1N1 broad-spectrum mRNA vaccine, and relates to the technical field of vaccine preparation, the amino acid sequence of the mRNA vaccine is shown as SEQ ID NO.1, and the nucleotide sequence of the mRNA vaccine is shown as SEQ ID NO.2, namely, the mRNA vaccine is obtained by connecting GGGSGGSGGGSGGGGS with conserved amino acid sequences of hemagglutinin HA and neuraminidase NA. The defects in the prior art are overcome, and the broad spectrum and the protection effect of the vaccine are improved, so that the vaccine can better cope with the immune escape of the latest variant in the future.
Owner:INST OF MEDICAL BIOLOGY CHINESE ACAD OF MEDICAL SCI

Recombinant HVT for co-expressing H9 subtype AIV HA gene, IBV S gene and IBDV VP2 gene and application thereof

The invention discloses a recombinant HVT for co-expressing an H9 subtype AIV HA gene, an IBV S gene and an IBDV VP2 gene and application of the recombinant HVT, and belongs to the technical field of medicine or veterinary medicine. The recombinant HVT is a recombinant HVT vaccine strain H30201 for co-expressing the H9 subtype AIV HA gene, the IBV S gene and the IBDV VP2 gene, which is obtained by inserting an expression cassette containing the H9 subtype AIV HA gene and the QX type IBV S gene between 95322-95323 nucleotides of an HVT FC126 strain and inserting an expression cassette containing the IBDV classic virulent strain VP2 gene between 112071-112088 nucleotides of an HVT genome at the same time through virus rescue. The invention also provides application of the recombinant HVT vaccine strain in preparation of vaccines for H9 subtype avian influenza, infectious bronchitis and infectious bursal disease.
Owner:INST OF URBAN AGRI CHINESE ACADEMY OF AGRI SCI +1

Construction method and application of recombinant herpesvirus turkey for co-expressing NDV F gene and H9 subtype AIV HA gene

The invention provides a construction method and application of a recombinant herpesvirus turkey for co-expressing an NDV (Newcastle Disease Virus) F gene and an H9 subtype AIV (Avian Influenza Virus) HA gene, and belongs to the field of genetic engineering vaccines. The recombinant clone technology is utilized, an expression framework containing a Newcastle disease virus gene VII type strain F gene and an H9 subtype avian influenza virus HA gene is inserted between 95322-95323 nucleotides or between 112071-112088 nucleotides of a turkey herpesvirus FC126 strain, and the recombinant clone with the F gene and HA gene expression framework inserted into a turkey herpesvirus genome is constructed and obtained. Recombinant turkey herpesvirus vaccine strains H20901 and H20902 for co-expressing the Newcastle disease virus F gene and the H9 subtype avian influenza virus HA gene are rescued and obtained by the recombinant turkey herpesvirus vaccine strain H20901 and H20902. The vaccine prepared from the recombinant turkey herpesvirus provided by the invention can provide dual protection for the Newcastle disease virus and the avian influenza virus, and has a good market application prospect.
Owner:INST OF URBAN AGRI CHINESE ACADEMY OF AGRI SCI +1

Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof

The invention is related to multivalent immunogenic compositions comprising more than one S. pneumoniae polysaccharide protein conjugates, wherein each of the conjugates comprises a polysaccharide from an S. pneumoniae serotype conjugated to a carrier protein, wherein the serotypes of S. pneumoniae are as defined herein. Also provided are methods for inducing a protective immune response in a human patient comprising administering the multivalent immunogenic compositions of the invention to the patient. The multivalent immunogenic compositions are useful for providing protection against S. pneumoniae infection and diseases caused by S. pneumoniae. The compositions of the invention are also useful as part of treatment regimes that provide complementary protection for patients that have been vaccinated with a multivalent vaccine indicated for the prevention of pneumococcal disease.
Owner:MERCK SHARP & DOHME LLC

Active immunization for treating atopic dermatitis

PCT designated stage expiredWO2025017537A1Antibody mimetics/scaffoldsVertebrate antigen ingredientsAtopic dermatitisActive immunization
An immunogenic fusion protein used for active immunization or a bivalent vaccine in the treatment of atopic dermatitis (AD) in a subject and a method thereof. The immunogenic fusion protein includes a IL31 polypeptide and at least one substance P polypeptide (SP). The invention is particularly useful for treating and / or preventing AD and symptoms related to AD including pruritus in mammals.
Owner:PRALONIR SAS

Severe fever with thrombocytopenia syndrome virus mRNA vaccine as well as preparation method and application thereof

The invention provides a chimeric bivalent SFTSV (severe fever with thrombocytopenia syndrome virus) mRNA (messenger ribonucleic acid) vaccine, which is characterized in that the vaccine co-expresses an SFTSV envelope protein precursor GPC and a nucleoprotein NP in series through a flexible joint. Through humoral immunity, cellular immunity and challenge protection effect evaluation, the effectiveness of the mRNA vaccine provided by the invention is verified. Research results show that the prepared SFTSV mRNA vaccine can generate a good immune protection effect by only needing one mRNA, has the characteristics of simple industrial production, easy quality control and the like, and is an ideal choice of the SFTSV vaccine.
Owner:UNIV OF SCI & TECH OF CHINA

Low-sugar coronavirus vaccine and methods thereof

The present disclosure relates to a low glycosylated spike protein and a vaccine designed to express the spike protein in vivo. The present disclosure also teaches a method for generating an immune response by utilizing the low glycosylated spike protein, which provides a broader protection across different variants. A method for identifying a glycan-shielded conserved peptide of a glycoprotein is also disclosed.
Owner:ROCK BIOMEDICAL INC +1

Development and application of a subunit vaccine for porcine contagious pleuropneumonia

The present invention relates to the field of veterinary vaccines, and discloses the development and application of a subunit vaccine for porcine contagious pleuropneumonia. The TbpB-C truncated protein and the AdhE whole protein selected in the antigen protein combination of the vaccine of the present invention are highly homologous in all APP serotypes, and are prepared into subunit vaccines that can provide cross protection to porcine actinobacillus pleuropneumoniae of different serotypes, and the protection rates against APP1 type and APP3 type strains are both 100%. The truncated proteins selected in the antigen protein combination of the present invention are successfully expressed in a soluble form after optimization, and are easy to express and purify in large quantities, thereby reducing production costs. The present invention lays a foundation for the development of an efficient, low-cost, broad-spectrum subunit vaccine for porcine contagious pleuropneumonia, and provides an effective technical means for the prevention and treatment of the disease.
Owner:JILIN UNIVERSITY

MRNA vaccines encoding varicella-zoster virus glycoprotein e

The present application provides an RNA encoding a varicella-zoster (VZV) glycoprotein E (gE) or a variant thereof, the RNA comprising a nucleotide sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity with the nucleotide sequence represented by any one of SEQ ID NO: 11-18. The eight mRNAs provided by the invention can translate in cells, the expression level of the generated VZV gE protein is high, and the mRNAs can induce a mouse to generate a high-titer gE specific IgG antibody in a manner of intramuscular injection into the body of the mouse through a preparation formed by encapsulating the lipidosome nanoparticles.
Owner:CNBG-VIROGIN BIOTECH (SHANGHAI) CO LTD